- Award ID
- 36E79724D0021
- Contractor
- ZYDUS PHARMACEUTICALS (USA) INC.
- Sub-agency / office
- Department of Veterans Affairs
- Award amount
- $0
- Period of performance
- May 18, 2024 – —
- NAICS
- 325412 — Pharmaceutical Preparation Manufacturing
- PSC
- PSC 6505
- Competition
- FULL AND OPEN COMPETITION · Set-aside: NO SET ASIDE USED. · 1 offers
- Pricing
- FIRM FIXED PRICE
- Financial breakdown
- Obligated $0 · Potential value $113,797,620 · Latest action obligation $0
MODIFICATION TO INCORPORATE SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS (APR 2026), INTO THE CONTRACT.
Most recent · Modification P00011 · Sep 9, 2026 · $0 action obligation · MODIFICATION TO INCORPORATE SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS (APR 2026), INTO THE CONTRACT. · 36E79724D0021
Modification P00010 · Apr 15, 2026 · $0 action obligation · EXERCISE OPTION YEAR TWO FOR 36E79724D0021 WITH NO PRICE CHANGES. THE PERIOD OF PERFORMANCE IS 5/18/2026 - 5/17/2027. · 36E79724D0021
Modification P00009 · Jan 14, 2026 · $0 action obligation · THIS MODIFICATION IS ISSUED TO INCORPORATE ZYDUS'S 2026 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JANUARY 1, 2026 - DECEMBER 31, 2026. · 36E79724D0021
Modification P00008 · Dec 8, 2025 · $0 action obligation · INCORPORATE 2026 FEDERAL CEILING PRICE IAW PUBLIC LAW 102-585 FOR DPP-4 SITAGLIPTIN TABLETS WITH ZYDUS PHARMACEUTICALS USA, INC. NO PRICE CHANGES TO THE NATIONAL CONTRACT. · 36E79724D0021
Modification P00007 · Apr 22, 2025 · $0 action obligation · EXERCISE OPTION YEAR ONE FOR 36E79724D0021 WITH NO PRICE CHANGES. THE PERIOD OF PERFORMANCE IS 5/18/2025 - 5/17/2026. · 36E79724D0021
Modification P00006 · Apr 17, 2025 · $0 action obligation · INCORPORATE 2025 FEDERAL CEILING PRICE IAW PUBLIC LAW 102-585 FOR DPP-4 SITAGLIPTIN TABLETS WITH ZYDUS PHARMACEUTICALS USA, INC. NO PRICE CHANGES TO THE NATIONAL CONTRACT. · 36E79724D0021
Modification P00005 · Apr 3, 2025 · $0 action obligation · THIS MODIFICATION IS ISSUED TO INCORPORATE ZYDUS 2025 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JANUARY 1, 2025 - DECEMBER 31, 2025. · 36E79724D0021
Modification P00004 · Nov 20, 2024 · $0 action obligation · BOTH THE 30 COUNT BOTTLES AND 90 COUNT BOTTLES WILL REMAIN ON THE CONTRACT 36E79724D0021.THE 90 COUNT BOTTLES ARE NOT REPLACING THE 30 COUNT BOTTLES. THE 90 COUNT BOTTLES WERE ADDED AS AN ALTERNATE BOTTLE SIZE. · 36E79724D0021
Modification P00003 · Oct 29, 2024 · $0 action obligation · 3 NDC ADDITIONS TO 36E79724D0021. THE 90CT BOTTLES WILL BE AT THE SAME PER TABLET PRICE AS THE 30CT BOTTLES. PERIOD OF PERFORMANCE IS EFFECTIVE 10-30-2024-05-17-2025. THE OLD NDC"S WILL REMAIN ON CONTRACT UNTIL THE PRODUCT HAS BEEN FULLY DEPLETED. · 36E79724D0021
Modification P00002 · Sep 18, 2024 · $0 action obligation · THIS MODIFICATION IS ISSUED TO INCORPORATE THE ZYDUS 2024 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JANUARY 1, 2024 - DECEMBER 31, 2024. · 36E79724D0021
Modification P00001 · Apr 4, 2024 · $0 action obligation · MODIFICATION FOR THE SUPPLEMENTAL CHANGES TO THE CRF PAYMENT SUBMITTAL AND SALES REPORTING REQUIREMENTS. · 36E79724D0021
Modification 0 · Mar 18, 2024 · $0 action obligation · NEW AWARD FOR DPP-4 SITAGLIPTIN WITH ZYDUS PHARMACEUTICALS (USA)INC. PERIOD OF PERFORMANCE IS 5/18/2024 - 5/17/2025 WITH FOUR ONE-YEAR OPTION PERIODS. · 36E79724D0021